Furthermore, a retrospective analysis involving 3232 newly diagnosed DLBCL patients treated with CIT, as recorded in the Danish Lymphoma Registry, demonstrated that incorporating β2M into the NCCN-IPI enhances the discriminatory performance of this prognostic tool [136]. The gene discussed is B2M; the disease is diffuse large B-cell lymphoma.